Showing 4511-4520 of 20465 results for "".
- Sequential Add-On Therapy and Risk Reclassification in PAHhttps://reachmd.com/news/sequential-add-on-therapy-risk-reclassification-pah/2487709/Key Takeaways Both noninvasive risk tools shifted toward lower-risk categories during follow-up after macitentan was added to prior sildenafil. WHO functional class improved and BNP decreased, while 6-minute walk distance remained essentially unchanged
- Aurenar Wins FDA Breakthrough Designation for V-Linkhttps://reachmd.com/news/aurenar-fda-breakthrough-v-link/2487710/Key Takeaways The FDA granted Breakthrough Device Designation to Aurenar’s V-Link System for adults with aneurysmal subarachnoid hemorrhage as an ICU adjunct intended to reduce cerebral vasospasm. V-Link remains investigational while development, comme
- Topical Rosacea Therapies Compared in Network Meta-Analysishttps://reachmd.com/news/topical-rosacea-therapies-compared-in-network-meta-analysis/2487701/Key Takeaways Ivermectin and encapsulated benzoyl peroxide were associated with greater lesion-count reduction and higher likelihood of Investigator Global Assessment success than metronidazole. Discontinuation due to adverse events or effects was broa
- Wildfire Smoke PM2.5 and Mortality in Contiguous United Stateshttps://reachmd.com/news/wildfire-smoke-pm25-and-mortality-in-contiguous-united-states/2487702/Key Takeaways Annual wildfire-smoke PM2.5 exposure was associated with a substantial all-cause mortality burden across the contiguous United States. Mortality rates increased for all studied outcomes except transport accidents and falls, which served a
- 4DMT Announces ASRS Presentation on 4D-150 Programhttps://reachmd.com/news/4dmt-announces-asrs-presentation-on-4d-150-program/2487698/Key Takeaways 4D Molecular Therapeutics announced a podium presentation on 4D-150 at ASRS 44 in Montreal, Canada. The listed session topic describes a two-year follow-up from the PRISM Phase 2b clinical trial in broad neovascular AMD and identifies 4D-
- Self-Directed Psychological Support After ACL Reconstructionhttps://reachmd.com/news/self-directed-psychological-support-acl-reconstruction/2487688/Key Takeaways Return to sport at 12 months was similar in participants receiving BANG plus usual care and usual care alone. Functional and psychological outcomes were not significantly different between groups. A 24-week internet-delivered
- Picankibart Shows Skin Clearance in Plaque Psoriasis: Analysishttps://reachmd.com/news/picankibart-shows-skin-clearance-in-plaque-psoriasis/2487695/A phase III study published in the Journal of the American Academy of Dermatology found that picankibart, an investigational interleukin (IL)-23p19 inhibitor, produced high rates of skin clearance with durable efficacy throu
- Polycaprolactone Dermal Fillers Show Significant Full-Face Rejuvenation Benefitshttps://reachmd.com/news/polycaprolactone-dermal-fillers-show-significant-full-face-rejuvenation-benefits/2487692/A retrospective image analysis suggests that polycaprolactone (PCL)-based dermal fillers may provide measurable improvements in facial contour and volume restoration across multiple anatomical regions during full-face rejuvenation, according to findings published online in the Journal of Cosm
- Commentary Proposes Path to Cutting Plastic Waste in Dermatology Researchhttps://reachmd.com/news/commentary-highlights-practical-route-to-cutting-plastic-waste-in-dermatology-research/2487685/The redesign of laboratory packaging to reduce plastic waste is a feasible near-term strategy for reducing plastic waste in skin-model research without disrupting validated experimental systems, according to a commentary in the Journal of Investigative Dermato
- Study: Dupilumab Shows Long-Term Disease Control in Pediatric Atopic Dermatitishttps://reachmd.com/news/study-dupilumab-shows-long-term-disease-control-in-pediatric-atopic-dermatitis/2487681/Children and adolescents with moderate-to-severe atopic dermatitis (AD) maintained improvements in disease signs and symptoms during 1 year of dupilumab treatment, according to a post hoc analysis of the ongoing phase 3 LIBERTY AD PED-OLE open-label extension study